Expression of USP9X in Non-small Cell Lung Cancer and Its Clinical Significance

PENG Jing, HU Qian, LIU Wei-ping. et al

Abstract

To investigate the expression and clinical significance of ubiquitin-specific protease 9X (USP9X) protein in non-small cell lung cancer (NSCLC). Methods USP9X proteins were detected in 71 cases of NSCLC and 20 cases of benign pulmonary tissues by immunohistochemical staining. The correlation between USP9X expression and 51 NSCLC clinicopathological parameters as well as survival rates were indicated. Results Higher rate 〔69.0% (49/71)〕 of the expression of USP9X was observed in NSCLC samples, compared with 20.0% (4/20) in benign pulmonary tissues (P<0.001). Furthermore, the expression of USP9X proteins was positively associated with both histological types and lymph node metastasis (P<0.05). The survival analysis showed that the survival rate was lower in patients with positive expressions of USP9X than in patients with negative expressions (P<0.05). USP9X expression, together with histological types and TNM stage was an independent predictor for overall survival in the multivariate Cox regression model (P<0.05). Conclusion Up-regulation of USP9X plays an important role in the invasion and progression of NSCLC and could be considered as a prognostic predictor for NSCLC.

 

Keywords: Lung neoplasms, USP9X, Survival Immunohistochemistry 

 

Full Text:

PDF


References


Hussain S. Zhang Y. Galardy PJ. DUBs and cancer:the role of eubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle,2009;8( 11): 1688-1697.

Xue LY. Hu N, Song YM, et al. Tissue microarray analysis reveals a tight correlation between protein expression pattern and progression of esophageal squamous cell carcinoma. BMC Cancer. 2006; 6:296.

Kapuria V, Peterson LF, Fang D. et al. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res,2010;70(22); 9265-9276.

Kerscher O. Felberbaum R. Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol,2006;22:159-180.

Reyes-Turcu FE, Ventii К H, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem. 2009; 78: 363-397. doi; 10. 1146/annurev. biochem. 78. 082307. 091526.

Komander D, Clague MJ, Urbe S. Breaking the chains; structure and function of the deubiquitinases. Nat Rev Mol Cell Biol,2009;10(8):550-563.

Quesada V, Diaz-Perales A, Gutierrez-Fernandez A, et al. Cloning and enzymatic analysis of 22 novel human ubiquitinspecific proteases. Biochem Biophys Res Commun, 2004;314(1):54-62.

Rolen U, Kobzeva V, Gasparjan N, et al. Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol Carcinog,2006;45(4):260-269.

Deng S, Zhou H, Xiong R. et al. Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics. Breast Cancer Res Treat.2007; 104 (1); 21-30.

Schwickart M. Huang X. Lill JR, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature.2010;463(7277):103-107.

Trivigno D. Essmann F. Huber SM. et al. Deubiquitinase USP9x confers radio resistance through stabilization of Mcl-1. Neoplasia,2010; 14(10) s893-904.

Sun H, Kapuria V, Peterson LF, et al. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood, 2011; 117(11): 3151 -3162.

Peddaboina C, Jupiter D. Fletcher S, et al. The downregulation of Mcl-1 via USP9Xinhibition sensitizes solid tumors to Bcl-xl inhibition. BMC Cancer, 2012; 12: 541. doi: 10. 1186/1471-2407-12-541.

Peng J, Hu Q. Liu WP. et al. USP9X expression correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma. Diagn Pathol. 2013; 8: 177. doi: 10. 1186/1746-1596-8-177.


Refbacks

  • There are currently no refbacks.